Pathway-27 Consortium


PATHWAY-27 includes 25 partners broadly distributed in Europe: west to east, south to north Europe, including one Candidate Country (Turkey). The EU Consortium consists of different organisation types, namely: Universities, Research Institutes and SMEs.

Partners in Germany



The Max Rubner-Institut (MRI) is a government-funded German research institution. Its primary task is to advise the Federal Ministry on matters of human nutrition and consumer policy, and to carry out the research needed as the basis of such advice. Research is conducted in the fields of nutrition, food science, nutrition behaviour and related fields. Special emphasis is placed on the elucidation of the role of food constituents including phytochemicals and their role in disease prevention. The Department of Physiology and Biochemistry of Nutrition of the MRI has extended experience to measure immunological, antioxidative, and anticarcinogenic activities of food constituents or diets at the cellular level, in animal models as well as in human intervention studies.
Previous experience related to the tasks The department runs a human nutrition ward fully equipped for controlled dietary intervention studies, short-term/bioavailability, long-tern/bioactivity. The MRI has facilities for volunteer characterization (dietary habits, physical activity, energy expenditure, body composition/DXA, cardiovascular/lung function, etc.) and detailed body fluid analysis (e.g. LC-MS/MS, GC-MS) of diet and function related markers.

Scientific responsible: PD Dr. Achim Bub, MD (


Project partner(s):


The Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ) enjoys a worldwide reputation for excellence in basic and translational cancer research, highlighted by the 2008 Nobel Prize for medicine to Harald zur Hausen. Founded in 1964, the DKFZ has nowadays a staff of 2300 persons, with more than 1040 scientists and approximately 1015 employees providing administrative and technical support. The research programme is concentrated on seven main research areas: signalling pathways, cell biology and cancer; structural and functional genomics; cancer risk factors and prevention; tumour immunology; innovative diagnosis, prevention and therapy; infection and cancer; and translational cancer research. . DKFZ has a strong record of participation in EU framework programmes. Within FP6 DKFZ is participating in about 60 projects with funding for the DKFZ of 24 Mio. €. Within FP7 DKFZ is participating in 31 projects with funding for the DKFZ of approx. 20 Mio. €.

Previous experience related to the tasks. Epigenetic characterization of major malignancies by using genome-wide screens for the identification of aberrant DNA methylation, characterization of candidate genes identified as epigenetic targets, elucidation of mechanisms of epigenetic gene regulation, development of mouse models relevant for epigenetic studies, development of novel biomarkers relevant for chemoprevention, early diagnosis and treatment response.
Analyses of early epigenetic changes (DNA methylation, histone acetylation) during carcinogenesis and the influence of dietary factors on these changes in cell culture, in animal models and in human intervention studies (nutri-epigenomics). State-of-the-art technology for quantitative methylation analysis, including MassARRAY technology based on MALDI-TOF mass spectrometry, methyl-CpG immunoprecipitation (MCIp) coupled with CpG island microarray analyses and next generation sequencing, quantitative real time PCR analysis, flow cytometry, siRNA and shRNA technology, demethylating agents for functional analyses.

Scientific responsible: Clarissa Gerhäuser (


Project partner(s):